Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital (Q57350145)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital	article

Statements

scholarly article

0 references

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

object named as

L. Klareskog

5

0 references

author name string

M. C. Wick

1

0 references

S. Ernestam

2

0 references

S. Lindblad

3

0 references

J. Bratt

4

0 references

R. F. van Vollenhoven

6

0 references

publication date

January 2005

0 references

Scandinavian Journal of Rheumatology

0 references

34

0 references

5

0 references

353-358

0 references

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Rheumatoid arthritis--a molecular understanding

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

New drugs for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO).

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026887

21 January 2018

Identifiers

10.1080/03009740510026887

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57350145&oldid=1793717033"